<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01074697</url>
  </required_header>
  <id_info>
    <org_study_id>GAND-emesis</org_study_id>
    <secondary_id>2009-014691-21</secondary_id>
    <nct_id>NCT01074697</nct_id>
  </id_info>
  <brief_title>Efficacy of Two Antiemetic Regimens in Patients Receiving Radiotherapy and Concomitant Weekly Cisplatin</brief_title>
  <acronym>GAND-emesis</acronym>
  <official_title>A Multinational, Randomized, Double-blind, Placebo-controlled Study to Investigate the Efficacy and Tolerability of Palonosetron and Dexamethasone Plus Fosaprepitant or Placebo in Patients Receiving Radiotherapy and Weekly Cisplatin.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Odense University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Helsinn Healthcare SA</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Odense University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      GAND-emesis is a multinational, randomized, double-blind, placebo-controlled, parallel-group
      study to investigate the efficacy and tolerability of a neurokinin1 receptor antagonist
      (fosaprepitant dimeglumine) in combination with an antiemetic (anti-nausea-and-vomiting)
      control regimen (palonosetron and dexamethasone) in patients with a gynaecological cancer
      diagnosis, who are scheduled to receive radiotherapy and weekly chemotherapy.

      The study aims at investigating if a three-drug antiemetic regimen is superior to a two-drug
      regimen (standard treatment) in preventing nausea and vomiting in patients receiving
      radiotherapy and weekly chemotherapy. A pilot study demonstrated that approximately 50% of
      patients will experience nausea and vomiting when offered a two-drug antiemetic regimen, and
      it is expected that addition of a third drug (a neurokinin1 receptor antagonist) can increase
      the proportion of patients with no vomiting in the course of combined chemo-radiotherapy.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2010</start_date>
  <completion_date type="Actual">April 2015</completion_date>
  <primary_completion_date type="Actual">April 2015</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To compare fosaprepitant dimeglumine, palonosetron, and dexamethasone with palonosetron, dexamethasone, and placebo with respect to efficacy; the proportion of subjects with no vomiting during five weeks of radiotherapy and concomitant weekly cisplatin.</measure>
    <time_frame>35 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To compare the fosaprepitant dimeglumine regimen and the control regimen in terms of the proportion of subjects with complete response in the 7 days following initiation of radiotherapy and concomitant weekly cisplatin.</measure>
    <time_frame>7 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To compare the fosaprepitant dimeglumine regimen and the control regimen in terms of the proportion of subjects with no significant nausea during five weeks of fractionated radiotherapy and concomitant weekly cisplatin at a dose of ≥ 40 mg/m2.</measure>
    <time_frame>35 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To compare the fosaprepitant dimeglumine regimen and the control regimen with respect to complete response in the 35 days following initiation of fractionated radiotherapy and concomitant weekly cisplatin at a dose of ≥ 40 mg/m2.</measure>
    <time_frame>35 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To compare the fosaprepitant dimeglumine regimen and the control regimen in terms of the proportion of subjects with no nausea during five weeks (35 days) of fractionated radiotherapy and concomitant weekly cisplatin at a dose of ≥ 40 mg/m2.</measure>
    <time_frame>35 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To compare the fosaprepitant dimeglumine regimen and the control regimen in terms of the number of days to first emetic episode.</measure>
    <time_frame>0-35 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To compare quality of life using the FLIE questionnaire.</measure>
    <time_frame>0-35 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To compare tolerability of both regimens.</measure>
    <time_frame>0-35 days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">246</enrollment>
  <condition>Nausea</condition>
  <condition>Vomiting</condition>
  <condition>Genital Neoplasms, Female</condition>
  <arm_group>
    <arm_group_label>Fosaprepitant dimeglumine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Saline water</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fosaprepitant dimeglumine</intervention_name>
    <description>Addition of fosaprepitant dimeglumine 150 mg IV single dose weekly (before chemotherapy) to dexamethasone and palonosetron.</description>
    <arm_group_label>Fosaprepitant dimeglumine</arm_group_label>
    <other_name>Palonosetron</other_name>
    <other_name>Dexamethasone</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Saline water</description>
    <arm_group_label>Saline water</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria: (abbreviated)

          1. The patient has a diagnosis cervical cancer.

          2. The patient understands the nature and purpose of this study and the study procedures
             and has signed informed consent.

          3. The patient is aged &gt; 18 years.

          4. The patient must be both chemo- and radiotherapy (RT) naïve. NB: previously low
             voltage RT or electron RT for non-melanoma skin cancers is allowed.

          5. The patient is scheduled to receive fractionated radiotherapy and concomitant weekly
             cisplatin at a dose of ≥ 40 mg/m2 for at least five weeks.

          6. Brachy therapy is scheduled to be initiated after the third cycle of weekly cisplatin,
             and preferentially after the fifth week of treatment.

          7. Chemotherapy with an emetic risk potential of minimal or mild (up to 30%) is allowed
             on days 1-4 (see ref. 14).

          8. The patient has a WHO Performance Status of ≤ 2.

        Exclusion Criteria: (abbreviated)

          1. The patient has a current malignant diagnosis other than cervical cancer, with
             exception of non-melanoma skin cancers.

          2. The patient is aged &lt; 18 years.

          3. The patient is scheduled to receive less than five weeks of fractionated radiotherapy
             and concomitant weekly cisplatin.

          4. Brachy therapy is planned to be initiated before the third cycle of weekly cisplatin.

          5. The patient has been previously treated with radiotherapy, and/or chemotherapy, with
             exception of treatment with low voltage RT or electron RT for non-melanoma skin
             cancers .

          6. The patient has a WHO Performance Status of &gt; 2.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jorn Herrstedt, MD, DMSci</last_name>
    <role>Study Director</role>
    <affiliation>Odense University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Christina Ruhlmann, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Odense University Hospial</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Dorothy Keefe, MD, FRACP</last_name>
    <role>Principal Investigator</role>
    <affiliation>Royal Adelaide Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Petra Feyer, MD, DMSci</last_name>
    <role>Principal Investigator</role>
    <affiliation>Vivantes Klinikum Neukölln in Berlin</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Thomas Broe Christensen, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Herlev Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Gunnar Kristensen, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Norwegian Radium Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Henrik Roed, MD, DMSci</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Finsen Centre, Copenhagen University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Felix Hilpert, MD, DMSci</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Schleswig-Holstein</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jacob C Lindegaard, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Oncology,Aarhus University Hospital, Aarhus, Denmark</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>RAH Cancer Centre, Royal Adelaide Hospital</name>
      <address>
        <city>Adelaide SA</city>
        <zip>5000</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Oncology</name>
      <address>
        <city>Aarhus</city>
        <zip>8000</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rigshospitalet, Finsen Centret</name>
      <address>
        <city>Copenhagen</city>
        <zip>2100</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Herlev Hospital</name>
      <address>
        <city>Herlev</city>
        <zip>2730</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Oncology, Odense University Hospital</name>
      <address>
        <city>Odense</city>
        <zip>5000</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vivantes Klinikum Neukolln</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitatsklinikum Schleswig Holstein</name>
      <address>
        <city>Kiel</city>
        <zip>24105</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Norwegian Radium Hospital</name>
      <address>
        <city>Oslo</city>
        <zip>0310</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Denmark</country>
    <country>Germany</country>
    <country>Norway</country>
  </location_countries>
  <verification_date>April 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 23, 2010</study_first_submitted>
  <study_first_submitted_qc>February 23, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 24, 2010</study_first_posted>
  <last_update_submitted>April 23, 2015</last_update_submitted>
  <last_update_submitted_qc>April 23, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 24, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Odense University Hospital</investigator_affiliation>
    <investigator_full_name>Christina Ruhlmann</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <keyword>Randomized Controlled Trial</keyword>
  <keyword>Serotonin Agonists</keyword>
  <keyword>Dexamethasone</keyword>
  <keyword>Receptors, Neurokinin-1</keyword>
  <keyword>Radiotherapy</keyword>
  <keyword>Cisplatin</keyword>
  <keyword>Prevention &amp; control</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vomiting</mesh_term>
    <mesh_term>Genital Neoplasms, Female</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cisplatin</mesh_term>
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Dexamethasone acetate</mesh_term>
    <mesh_term>Fosaprepitant</mesh_term>
    <mesh_term>Aprepitant</mesh_term>
    <mesh_term>BB 1101</mesh_term>
    <mesh_term>Palonosetron</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

